| Name | Title | Contact Details |
|---|
Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).
HNP Pharmaceuticals is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neponset Controls Inc is a Foxboro, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Afexa Life Sciences Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity.